Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZomedicaZOMDF -0.01% Equity-to-Asset is 0.91 as of Jun. 2026, which is 1% below its 10-year median of 0.92. The stock has 2 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Zomedica ranks better than 94.5% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Zomedica's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $107.28 Mil. Zomedica's Total Assets for the quarter that ended in Jun. 2026 was $118.15 Mil.
Therefore, Zomedica's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.91.
The historical rank and industry rank for Zomedica's Equity-to-Asset or its related term are showing as below:
ZOMDF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.32 Med: 0.92 Max: 0.99
Current: 0.91
During the past 13 years, the highest Equity to Asset Ratio of Zomedica was 0.99. The lowest was -0.32. And the median was 0.92.
ZOMDF's Equity-to-Asset is ranked better than 94.5% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs ZOMDF: 0.91
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Zomedica Equity-to-Asset Related Terms
Zomedica Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Zomedica's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZOMDF vs SERA, HYPR, OM: Equity-to-Asset Comparison
For the Medical Devices subindustry, Zomedica's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zomedica Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Zomedica's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Zomedica's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zomedica (ZOMDF) has a Equity-to-Asset of 0.91 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zomedica and its competitors. This is near median its historical median of 0.92. According to the industry distribution chart, Zomedica ranks #47 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 5.5%.
Is Zomedica's Equity-to-Asset too high?
Zomedica's current Equity-to-Asset of 0.91 is near median its 10-year median of 0.92. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Zomedica's value of 0.91 is 42.2% above this industry median. Based on the distribution chart, Zomedica ranks #47 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Zomedica's Equity-to-Asset compare to SERA and HYPR?
According to the Medical Devices & Instruments industry distribution chart, Zomedica ranks #47 out of 854 companies for Equity-to-Asset. This places Zomedica in the top 6% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.64. Zomedica's value of 0.91 is 42.2% above this benchmark. While the company's 10-year median is 0.92 vs. the industry median of 0.64, Zomedica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zomedica's current Equity-to-Asset of 0.91 is 42.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Zomedica and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zomedica's current Equity-to-Asset is 0.91, which is near median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.18, compared to a current price of $0.08 — trading 53.7% below its estimated fair value. The current Equity-to-Asset is 0.91, which is near median its 10-year median of 0.92 and 42.2% above the Medical Devices & Instruments industry median of 0.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Zomedica (ZOMDF), the current Equity-to-Asset is 0.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZOMDF has been successfully added to your 
